Skip to main content
Premium Trial:

Request an Annual Quote

ID Biomedical, Third Wave Settle Patent Infringement Case

NEW YORK, Oct 23 - Third Wave Technologies said Monday it would pay $4 million in cash and issue $6 million worth of its stock to ID Biomedical in exchange for the company’s commitment to drop a patent infringement lawsuit against Third Wave and its Invader line of products.

Third Wave has also dismissed its action against ID Biomedical and has agreed not to challenge the ownership or validity of ID Biomedical’s patents.

" We are pleased to have settled these matters with ID Biomedical," Lance Fors, president and CEO of Third Wave, said in a statement. " The dismissal of the cases not only frees us from this litigation burden, but also allows our management team to focus on continuing to build our business."

In September, ID Biomedical of Vancouver filed a patent infringement suit against Third Wave Technologies of Madison, Wis., for its use of a patented nucleic acid amplification and detection technology. The Canadian company claimed that Third Wave’s Invader assay products and technology violated elements of a patent that had been exclusively licensed to ID Biomedical.

ID Biomedical, which has developed its Cycling Probe Technology gene identification system using knowledge covered in the patent, said that Third Wave has developed several thousand assay products using the allegedly infringing Invader technology.

Third Wave develops and provides DNA and RNA analysis technologies for use in genome research, pharmacogenomics, and clinical applications.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.